Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Moestue, Siver A ^a,b   Dam, Cornelia G ^a   Gorad, Saurabh S ^a   Kristian, Alexandr ^c   Bofin, Anna ^a   Mælandsmo, Gunhild M ^c,d   Engebråten, Olav ^c   Gribbestad, Ingrid S ^a   Bjørkøy, Geir ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BIOLOGICAL MARKER; GLUCOSE; GLYCEROPHOSPHORYLCHOLINE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHORYLCHOLINE; PROTEIN KINASE B; DACTOLISIB; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL LIKE BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LACTATE BLOOD LEVEL; LONG TERM CARE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; NEOPLASMS, BASAL CELL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; NEOPLASMS, BASAL CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874358175     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3391     Document Type: Article

References (65)

1. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41:40-47.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728. 10.1002/cncr.22618, 17387718.
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948. 10.1056/NEJMra1001389, 21067385.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
7. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562. 10.1038/nrc2664, 19629070.
8. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
9. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011, 13:224. 10.1186/bcr3039, 3315683, 22114931.
10. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296. 10.1038/nrg3199, 22473468.
11. Beloueche-Babari M, Workman P, Leach MO. Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents. Cell Cycle 2011, 10:2883-2893. 10.4161/cc.10.17.17192, 21857160.
12. Moestue S, Engebraaten O, Gribbestad IS. Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy. Mol Oncol 2011, 5:224-241. 10.1016/j.molonc.2011.04.001, 21536506.
13. Tennant DA, Duran RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009, 30:1269-1280. 10.1093/carcin/bgp070, 19321800.
14. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008, 65:3981-3999. 10.1007/s00018-008-8224-x, 18766298.
15. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
16. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, Hupe P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10:R101. 10.1186/bcr2204, 2656897, 19055754.
17. Moulder SL. Does the PI3K pathway play a role in basal breast cancer?. Clin Breast Cancer 2010, 10:S66.
18. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009, 3:469-482. 10.1016/j.molonc.2009.07.003, 19713161.
19. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967. 10.1158/1535-7163.MCT-09-1012, 20571069.
20. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De PA, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863. 10.1158/1535-7163.MCT-08-0017, 18606717.
21. Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Kruger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging 2012, 35:1098-1107. 10.1002/jmri.23507, 22170753.
22. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Soiland H, Baak JP. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 2007, 20:1307-1315. 10.1038/modpathol.3800972, 17917671.
23. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19:30-40. 10.1002/nbm.992, 16229059.
24. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
25. Grinde MT, Moestue SA, Borgan E, Risa O, Engebraaten O, Gribbestad IS. 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR Biomed 2011, 24:1243-1252. 10.1002/nbm.1683, 21462378.
26. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Borresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433. 10.1186/1471-2407-10-433, 2931488, 20716336.
27. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672.
28. Moestue S, Nunez P, Healey A, Bjerke R, Indrevoll B, Skotland T, Hustvedt SO. Whole-body section fluorescence imaging - a novel method for tissue distribution studies of fluorescent substances. Contrast Media Mol Imaging 2009, 4:73-80. 10.1002/cmmi.264, 19142979.
29. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005, 11:4338-4340. 10.1158/1078-0432.CCR-05-0422, 15958615.
30. US National Institutes of Health. , http://www.clinicaltrials.gov
31. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30:3222-3233. 10.1038/onc.2011.42, 21358673.
32. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373. 10.1038/nature11706, 23151579.
33. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
34. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033. 10.1126/science.1160809, 2849637, 19460998.
35. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72. 10.1016/S0968-0004(98)01344-9, 10098401.
36. Deberardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20. 10.1016/j.cmet.2007.10.002, 18177721.
37. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008, 65:3981-3999. 10.1007/s00018-008-8224-x, 18766298.
38. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899. 10.1158/0008-5472.CAN-03-2904, 15172999.
39. Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF. Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest 2005, 85:1457-1470.
40. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 2006, 5:187-196. 10.1158/1535-7163.MCT-03-0220, 16432178.
41. Serganova I, Rizwan A, Ni X, Thakur SB, Vider J, Russell J, Blasberg R, Koutcher JA. Metabolic imaging: a link between lactate dehydrogenase a, lactate, and tumor phenotype. Clin Cancer Res 2011, 17:6250-6261. 10.1158/1078-0432.CCR-11-0397, 21844011.
42. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Cunningham CH, Deberardinis RJ, Green GG, Leach MO, Rajan SS, Rizi RR, Ross BD, Warren WS, Malloy CR. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011, 13:81-97. 3033588, 21403835.
43. Glunde K, Jiang L, Moestue SA, Gribbestad IS. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed 2011, 24:673-690. 3146026, 21793073.
44. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011, 11:835-848.
45. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
46. Jimenez B, del PL, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 1995, 57:141-149. 10.1002/jcb.240570114, 7721953.
47. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 2010, 102:941-946. 10.1038/sj.bjc.6605588, 2844037, 20234370.
48. Wen ZH, Su YC, Lai PL, Zhang Y, Xu YF, Zhao A, Yao GY, Jia CH, Lin J, Xu S, Wang L, Wang XK, Liu AL, Jiang Y, Dai YF, Bai XC. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. Oncogene 2013, 32:160-170. 10.1038/onc.2012.47, 22349822.
49. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 2010, 29:139-149. 10.1038/onc.2009.317, 19855431.
50. Park JB, Lee CS, Jang JH, Ghim J, Kim YJ, You S, Hwang D, Suh PG, Ryu SH. Phospholipase signalling networks in cancer. Nat Rev Cancer 2012, 12:782-792. 10.1038/nrc3379, 23076158.
51. Ramirez de MA, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004, 64:6732-6739. 10.1158/0008-5472.CAN-04-0489, 15374991.
52. Rodriguez-Gonzalez A, Ramirez de MA, Fernandez F, Ramos MA, del Carmen NM, Campos J, Lacal JC. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003, 22:8803-8812. 10.1038/sj.onc.1207062, 14654777.
53. Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of response to targeted treatment in cancer cells. NMR Biomed 2011, 24:648-672.
54. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
55. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev 2010, 110:3043-3059. 10.1021/cr9004007, 2877696, 20384323.
56. Keshari KR, Tsachres H, Iman R, Delos SL, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment. NMR Biomed 2011, 24:691-699. 10.1002/nbm.1738, 21793074.
57. Moestue SA, Giskeodegard GF, Cao MD, Bathen TF, Gribbestad IS. Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proc Natl Acad Sci USA 2012, 109:E2506. 10.1073/pnas.1208226109, 22851771.
58. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, Leach MO. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget 2010, 1:185-197. 2965833,2965833, 21037799.
59. Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 2009, 158:588-600. 10.1111/j.1476-5381.2009.00345.x, 2757699, 19663881.
60. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008, 10:303-313. 2288545, 18392140.
61. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 2006, 5:1325-1334. 10.1158/1535-7163.MCT-05-0494, 16731766.
62. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramirez de MA, Lacal JC, Workman P, Leach MO. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010, 70:5507-5517. 10.1158/0008-5472.CAN-09-4476, 2896552, 20551061.
63. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010, 12:559-569. 10.1093/neuonc/nop058, 2940638, 20156803.
64. Wijnen JP, Scheenen TW, Klomp DW, Heerschap A. 31P magnetic resonance spectroscopic imaging with polarisation transfer of phosphomono- and diesters at 3 T in the human brain: relation with age and spatial differences. NMR Biomed 2010, 23:968-976. 10.1002/nbm.1523, 20669234.
65. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.